PUBLIC COMPANY
saveDaiichi Sankyo Co Ltd
updated 2mo ago
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
community read0 votes
🐶 often sniffed alongside
top 7pipeline
17
marketed
4
phase 3
2
catalysts ytd
4
approvals ytd
1
recalls ytd
0
Pipeline(17)
view full pipeline →pipeline depth17 products
3Phase 13Phase 22Phase 34Marketed3Unknown2pre_registration
Marketed
edoxaban tosylate
Atrial Fibrillation
Marketedpexidartinib hydrochloride
Tenosynovial Giant Cell Tumor
Marketedquizartinib dihydrochloride
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Marketedtrastuzumab deruxtecan
Metastatic Colorectal Cancer
Receptor tyrosine-protein kinase erbB-2DNA topoisomerase 1
Phase 3patritumab deruxtecan
Human Epidermal Growth Factor Receptor 2 Negative Breast…
Receptor tyrosine-protein kinase erbB-3DNA topoisomerase 1
Phase 3raludotatug deruxtecan
Adenocarcinoma Of The Gastroesophageal Junction
Phase 2DS-3939
Solid Tumor
Phase 2DS-7011
Cutaneous Lupus Erythematosus
Phase 2valemetostat
Non-Small Cell Lung Cancer
Phase 1DS-2243
Solid Tumor
Phase 1DS-5361
Head And Neck Squamous Cell Carcinoma (HNSC)
Phase 1DS-9051
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
no news has mentioned this company yet
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that